Trial Profile

A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-2 Study: Near Eye-vision Acuity Restoration)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jul 2026 According to an Orasis Pharmaceuticals media release, Orasis Pharmaceuticals and Aspen Australia submitted a New Drug Application to Therapeutic Goods Administration (TGA), Australia for review and approval of pilocarpine hydrochloride ophthalmic solution 0.4% (BESKA) for the treatment of presbyopia in adults.
15 Jul 2026 Results presented in the Orasis Pharmaceuticals media release.
11 Jan 2024 Results of pooled analysis ( n=613 from studies NCT04599933 and NCT04599972) assessing safety and efficacy of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia published in the Clinical Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com